These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 32880196)
1. Niraparib in the treatment of previously treated advanced ovarian, fallopian tube or primary peritoneal cancer. Rimel BJ; Dockery L; Randall LM; Moore K Future Oncol; 2020 Nov; 16(33):2701-2711. PubMed ID: 32880196 [TBL] [Abstract][Full Text] [Related]
2. Niraparib for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Kerliu L; Myruski S; Bhatti A; Soni P; Petrosius P; Pervanas HC; Horton ER Ann Pharmacother; 2020 Oct; 54(10):1010-1015. PubMed ID: 32172572 [TBL] [Abstract][Full Text] [Related]
3. Niraparib: First Global Approval. Scott LJ Drugs; 2017 Jun; 77(9):1029-1034. PubMed ID: 28474297 [TBL] [Abstract][Full Text] [Related]
4. Niraparib: A Review in Ovarian Cancer. Heo YA; Duggan ST Target Oncol; 2018 Aug; 13(4):533-539. PubMed ID: 30073633 [TBL] [Abstract][Full Text] [Related]
5. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Moore KN; Secord AA; Geller MA; Miller DS; Cloven N; Fleming GF; Wahner Hendrickson AE; Azodi M; DiSilvestro P; Oza AM; Cristea M; Berek JS; Chan JK; Rimel BJ; Matei DE; Li Y; Sun K; Luptakova K; Matulonis UA; Monk BJ Lancet Oncol; 2019 May; 20(5):636-648. PubMed ID: 30948273 [TBL] [Abstract][Full Text] [Related]
6. A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial. Gonzalez Martin A; Sanchez Lorenzo L; Colombo N; dePont Christensen R; Heitz F; Meirovitz M; Selle F; van Gorp T; Alvarez N; Sanchez J; Marqués C Int J Gynecol Cancer; 2021 Apr; 31(4):617-622. PubMed ID: 33318079 [TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of niraparib for ovarian cancer: a single-center observational study from China. Ni J; Cheng X; Zhao Q; Dai Z; Xu X; Guo W; Gu H; Zhou R; Wang Y; Chen X J Ovarian Res; 2021 May; 14(1):68. PubMed ID: 33993885 [TBL] [Abstract][Full Text] [Related]
8. In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma. AlHilli MM; Becker MA; Weroha SJ; Flatten KS; Hurley RM; Harrell MI; Oberg AL; Maurer MJ; Hawthorne KM; Hou X; Harrington SC; McKinstry S; Meng XW; Wilcoxen KM; Kalli KR; Swisher EM; Kaufmann SH; Haluska P Gynecol Oncol; 2016 Nov; 143(2):379-388. PubMed ID: 27614696 [TBL] [Abstract][Full Text] [Related]
9. Human mass balance study and metabolite profiling of van Andel L; Zhang Z; Lu S; Kansra V; Agarwal S; Hughes L; Tibben MM; Gebretensae A; Lucas L; Hillebrand MJX; Rosing H; Schellens JHM; Beijnen JH Invest New Drugs; 2017 Dec; 35(6):751-765. PubMed ID: 28303528 [TBL] [Abstract][Full Text] [Related]
10. FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy. Ison G; Howie LJ; Amiri-Kordestani L; Zhang L; Tang S; Sridhara R; Pierre V; Charlab R; Ramamoorthy A; Song P; Li F; Yu J; Manheng W; Palmby TR; Ghosh S; Horne HN; Lee EY; Philip R; Dave K; Chen XH; Kelly SL; Janoria KG; Banerjee A; Eradiri O; Dinin J; Goldberg KB; Pierce WF; Ibrahim A; Kluetz PG; Blumenthal GM; Beaver JA; Pazdur R Clin Cancer Res; 2018 Sep; 24(17):4066-4071. PubMed ID: 29650751 [TBL] [Abstract][Full Text] [Related]
11. Niraparib for the treatment of ovarian cancer. Essel KG; Moore KN Expert Rev Anticancer Ther; 2018 Aug; 18(8):727-733. PubMed ID: 29911447 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic drug evaluation of niraparib for the treatment of ovarian cancer. Longoria TC; Tewari KS Expert Opin Drug Metab Toxicol; 2018 May; 14(5):543-550. PubMed ID: 29620474 [TBL] [Abstract][Full Text] [Related]
13. Niraparib for the treatment of ovarian cancer. Kanjanapan Y; Lheureux S; Oza AM Expert Opin Pharmacother; 2017 Apr; 18(6):631-640. PubMed ID: 28299955 [TBL] [Abstract][Full Text] [Related]